跳至主要内容
临床试验/KCT0003563
KCT0003563招募中未知

Efficacy comparison of metronidazole-based triple and bismuth-based quadruple therapy for clarithromycin resistant-Helicobacter pylori infection: Randomized Controlled Trial

Kangdong Sacred Heart Hospital0 个研究点目标入组 660 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
入组人数
660

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 85(Year)(—)
性别
All

入选标准

  • Aged 19-85 subjects who underwent upper endoscopy and confirmed H. pylori infection by rapid urease test (CLOtest, Pronto Dry New; Medical Instruments Corp, Herford, Germany).
  • The clinical diagnosis are as follows;
  • H. pylori infected gastritis (including atrophic gastritis, family history of gastric cancer),
  • Peptic ulcer disease,
  • Gastric Mucosa-Associated Lymphoid Tissue(MALT) lymphoma,
  • Early gastric cancer or gastric adenoma who underwent endoscopic mucosal dissection

排除标准

  • Patients will be excluded if they had received
  • H. pylori eradication therapy within 1 year;
  • antibiotics within 4 weeks;
  • had a surgery of gastric cancer;
  • malignant tumors other than gastric cancer within 5 years of enroll;
  • severe systemic disorder such as end stage renal disease or liver cirrhosis,
  • hematologic disease,
  • central nervous system infection, organic neurologic disease,
  • infectious mononucleosis ;
  • history of allergic reaction to treatment drug;
  • current taking a drug of contraindication to treatment drug
  • pregnancy and lactating women;

研究者

相似试验